dazoxiben has been researched along with 6-(4-(2-(((4-chlorophenyl)sulfonyl)amino)ethyl)phenyl)-6-(3-pyridyl)hex-5-enoic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De La Cruz, JP; Moreno, A; Ruiz-Ruiz, MI; Sánchez De La Cuesta, F | 1 |
| Arrebola, MM; De La Cruz, JP; Escalante, R; Guerrero, A; Sánchez de La Cuesta, F; Villalobos, MA | 1 |
2 other study(ies) available for dazoxiben and 6-(4-(2-(((4-chlorophenyl)sulfonyl)amino)ethyl)phenyl)-6-(3-pyridyl)hex-5-enoic acid
| Article | Year |
|---|---|
Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Blood Glucose; Chlorobenzenes; Collagen; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Enzyme Inhibitors; Imidazoles; Male; Platelet Aggregation; Pyridines; Rats; Rats, Wistar; Receptors, Thromboxane; Retinal Vessels; Thromboxane B2; Thromboxane-A Synthase | 2000 |
Effects of the selective inhibition of platelet thromboxane synthesis on the platelet-subendothelium interaction.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Animals; Aspirin; Blood Platelets; Chlorobenzenes; Cyclooxygenase Inhibitors; Dinoprost; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Imidazoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyridines; Rabbits; Receptors, Thromboxane; Thromboxane B2; Thromboxane-A Synthase; Thromboxanes | 2002 |